FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1287-1288 November 9, 1995 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Perrine, S. P. Related Article by Sher, G. D. PubMed Citation

To the Editor: Sher et al. (June 15 issue)¹ may have drawn premature conclusions about the potential efficacy of butyrate in treating the -hemoglobinopathies, for several reasons. The patients in the study did not receive any iron supplements, according to the report and other presentations by the authors. Iron has been shown to be required for responses to other agents that stimulate fetal hemoglobin.² We observe moderate responses to butyrate, even in iron-overloaded patients, with a low level of iron supplementation, whereas twofold greater responses occur with increased supplementation.

More important, the regimen of butyrate used in the study by . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Dempsey, N. J., Ojalvo, L. S., Wu, D. W., Little, J. A. (2003). Induction of an embryonic globin gene promoter by short-chain fatty acids. Blood 102: 4214-4222 [Abstract] [Full Text]